Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac136 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Ji Hyeon Ju und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Pfizer Pharmaceuticals Korea Ltd.
Abstract (Originalsprache)
Objectives
The aim of this article is to assess the safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in routine clinical settings in Korea.
Methods
This is a prospective, multi-centre post-marketing surveillance study. Data were prospectively collected within 6 months after the start of tofacitinib therapy. Safety was evaluated based on the presence of adverse events (AEs) observed in patients who received at least one dose of tofacitinib. Effectiveness was assessed according to the proportion of patients who achieved low disease activity and remission, American College of Rheumatology 20 criteria (ACR20), European League Against Rheumatism (EULAR) response, and change of Disease Activity Score in 28 Joints (DAS28).
Results
The incidence rates [patients with events per 100 patient-years (PY)] of AEs and serious AEs were 56.92 and 10.69, respectively. Regarding AEs of special interest, the incidence rates were 4.33 per 100 PY for serious infections and infestations, 5.78 per 100 PY for herpes zoster, no event of tuberculosis, 0.29 per 100 PY for malignancy, 0.29 per 100 PY for venous thromboembolism (one event of deep vein thrombosis and no event of pulmonary embolism), 0.87 per 100 PY for major adverse cardiovascular event, and 0.58 per 100 PY for mortality. Moreover, ∼40.48% and 21.60% of patients achieved low disease activity and remission of DAS28-erythrocyte sedimentation rate. The EULAR response was classified as good responders with 39.12% in the DAS28-erythrocyte sedimentation rate.
Conclusions
The benefit/risk profile of tofacitinib in adult patients with rheumatoid arthritis in routine clinical settings in Korea was similar to long-term clinical trial data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
- Pfizer Pharmaceuticals Korea Ltd, Seoul, Korea.
- Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea.
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.
ORCID-Profile: Eun Bong Lee
Förderung
- Pfizer Pharmaceuticals Korea Ltd
Zitieren
APA
Ju, J. H., Sung, Y. K., Jo, J. Y., Jeon, J. Y., Yoo, H. J., & Lee, E. B. (2023). Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study. Modern Rheumatology. https://doi.org/10.1093/mr/roac136
Vancouver
Ju JH, Sung YK, Jo JY, Jeon JY, Yoo HJ, Lee EB. Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study. Modern Rheumatology. 2023. doi:10.1093/mr/roac136
BibTeX
@article{Ju2023,
author = {Ju, Ji Hyeon and Sung, Yoon-Kyoung and Jo, Joo-Young and Jeon, Ja-Young and Yoo, Hyun-Jeong and Lee, Eun Bong},
title = {Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac136}
}
EUVIMED